Azvudine tablets

Azvudine, also known as Azifudine, was invented by Professor Chang Junbiao and jointly developed by Henan Zhenshi Biotechnology Co., Ltd., Zhengzhou University, Henan Normal University, and Henan Academy of Sciences High-Tech Research Center [7]. It is an HIV reverse transcriptase (RT) inhibitor and a new generation of AIDS treatment drugs that are world-leading and China’s first [6].
In February 2020, after Azvudine was found to be effective against the new coronavirus, it was approved by the National Medical Products Administration to conduct a Phase III clinical trial against the new coronavirus in April 2020 [3]. In July 2021, Azvudine, as an anti-HIV drug, was approved for marketing and is the world’s first dual-target anti-AIDS innovative drug [4].
On July 25, 2022, the National Medical Products Administration conditionally approved the registration application of Henan Zhenshi Biotechnology Co., Ltd.’s Azvudine tablets to add the indication of COVID-19 treatment [9].